The value proposition of digital medicine2018-02-09T17:52:49+00:00

The value proposition of digital medicine

“The value proposition of these drugs that digitally track patient adherence to medication was undefined and untested.”

Challenge

Patients with mental illness often rely on antipsychotic medications to improve their symptoms, but realizing the full benefit of these therapies depends on patient adherence. Not all physicians regularly ask patients about their adherence to their antipsychotics and even among those who do, patient self-reports are not always reliable. New technologies, however, enable providers to have real-time monitoring of patient adherence to treatments. The value proposition of these drugs that digitally track patient adherence to medication was undefined and untested.

Response

PHE collaborated with a manufacturer of a treatment that digitally tracks medication adherence, to quantify the value that reliable information on drug adherence provides to physicians, insurers, and patients themselves.

Results

PHE developed a model based on healthcare provider surveys and real-world utilization data to demonstrate how accurate patient adherence information improved provider decision-making. The model showed that better treatment decisions saved payers up to $9107 annually, depending on the type of provider and patient. PHE also employed group-based trajectory modeling to show how patient adherence data could be used to reliably predict future patient behavior and better adjust treatment decisions accordingly.

Impact

PHE’s research was vetted and published in 3 journal articles. The results of the research demonstrated that digital medicine tracking technologies provide economic value to payers and patients in addition to improving treatment decisions by providers. At the time the research was conducted, digital medicine technology was not FDA approved but since this research, Abilify MyCite (aripiprazole tablets with sensor) has been approved by the FDA for treatment of schizophrenia, bipolar I disorder, and depression.

PHE’s research supported the value proposition of digital medicines, even before their launch to market.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK